Hangzhou Synrx Therapeutics Biomedical Technology Co., Ltd

This early-phase study tests a new oral drug called SYN818 combined with olaparib in 110 adults with advanced solid tumors, including ovarian and breast cancers that have BRCA mutations or related DNA repair problems. The main goals are to find a safe dose and check for side effe…